UY33304A - Compuestos heterocíclicos y sus usos - Google Patents

Compuestos heterocíclicos y sus usos

Info

Publication number: UY33304A
Authority: UY; Uruguay
Prior art keywords: inflammatory; restricted; disorders; heterocyclic compounds; conditions
Prior art date: 2010-04-02

Application number

UY0001033304A

Other languages

English (en)

Spanish (es)

Inventor

He Xiao

Timothy David Cushing

Jason A Duquette

Lohman Julia

Shin Youngsook

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-02

Filing date

2011-03-30

Publication date

2011-10-31

2011-03-30 Application filed by Amgen Inc filed Critical Amgen Inc

2011-10-31 Publication of UY33304A publication Critical patent/UY33304A/es

Links

150000002391 heterocyclic compounds Chemical class 0.000 title 1
230000002757 inflammatory effect Effects 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
206010027654 Allergic conditions Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000003950 B-cell lymphoma Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010020853 Hypertonic bladder Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000025747 Rheumatic disease Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
230000009610 hypersensitivity Effects 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UY0001033304A 2010-04-02 2011-03-30 Compuestos heterocíclicos y sus usos UY33304A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32037810P	2010-04-02	2010-04-02

Publications (1)

Publication Number	Publication Date
UY33304A true UY33304A (es)	2011-10-31

Family

ID=43982368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UY0001033304A UY33304A (es)	2010-04-02	2011-03-30	Compuestos heterocíclicos y sus usos

Country Status (25)

Country	Link
US (1)	US8575183B2 (fr)
EP (1)	EP2552908A2 (fr)
JP (1)	JP2013540099A (fr)
KR (1)	KR20130103309A (fr)
CN (1)	CN103221403A (fr)
AR (1)	AR081448A1 (fr)
AU (1)	AU2011235031B2 (fr)
BR (1)	BR112012025164A2 (fr)
CA (1)	CA2793897A1 (fr)
CL (1)	CL2012002769A1 (fr)
CO (1)	CO6630161A2 (fr)
CR (1)	CR20120562A (fr)
EA (1)	EA201291005A1 (fr)
IL (1)	IL222288A0 (fr)
MA (1)	MA34212B1 (fr)
MX (1)	MX2012011387A (fr)
MY (1)	MY184620A (fr)
PE (1)	PE20130339A1 (fr)
PH (1)	PH12012501922A1 (fr)
SG (1)	SG184354A1 (fr)
TN (1)	TN2012000449A1 (fr)
TW (1)	TW201202219A (fr)
UY (1)	UY33304A (fr)
WO (1)	WO2011123751A2 (fr)
ZA (1)	ZA201207341B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2845856A1 (fr)	2009-06-29	2015-03-11	Incyte Corporation	Pyrimidinones en tant qu'inhibiteurs de PI3K
US8759359B2 (en)	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (fr)	2010-04-14	2013-02-20	Incyte Corporation	Dérivés condensés en tant qu'inhibiteurs de i3
WO2011163195A1 (fr)	2010-06-21	2011-12-29	Incyte Corporation	Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k
AU2011343712B2 (en)	2010-12-16	2015-09-17	Genentech, Inc.	Tricyclic PI3k inhibitor compounds and methods of use
TW201249844A (en)	2010-12-20	2012-12-16	Incyte Corp	N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
RU2013138835A (ru) *	2011-02-09	2015-03-20	Ф. Хоффманн-Ля Рош Аг	Гетероциклические соединения в качестве ингибиторов pi3 киназы
WO2012125629A1 (fr)	2011-03-14	2012-09-20	Incyte Corporation	Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
EA031153B1 (ru)	2011-06-10	2018-11-30	Мерк Патент Гмбх	Применение пиримидиновых соединений с btk ингибирующей активностью
UA121539C2 (uk)	2011-09-02	2020-06-25	Інсайт Холдинґс Корпорейшн	Гетероцикліламіни як інгібітори рі3к
JP6117235B2 (ja)	2011-12-15	2017-04-19	ノバルティスアーゲー	Ｐｉ３ｋの活性または機能の阻害剤の使用
US9493464B2 (en) *	2012-02-29	2016-11-15	The Scripps Research Institute	Wee1 degradation inhibitors
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9309243B2 (en)	2012-07-13	2016-04-12	Ucb Biopharma Sprl	Imidazopyridine derivatives as modulators of TNF activity
WO2014072937A1 (fr)	2012-11-08	2014-05-15	Rhizen Pharmaceuticals Sa	Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma
AU2013364070B2 (en)	2012-12-21	2016-10-27	Gilead Calistoga Llc	Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
TW201441216A (zh)	2012-12-21	2014-11-01	Gilead Calistoga Llc	肌醇磷酯３－激酶的抑制劑
TR201806822T4 (tr)	2013-06-14	2018-06-21	Gilead Calistoga Llc	Fosfatidilinositol 3-kinaz inhibitörleri.
CN104418849B (zh) *	2013-09-02	2020-04-21	广东东阳光药业有限公司	取代的氨基嘧啶类化合物及其使用方法和用途
EP3046921A4 (fr) *	2013-09-22	2017-02-22	Calitor Sciences, LLC	Composés d'aminopyrimidine substituée et procédés d'utilisation
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
SG11201610770PA (en)	2014-07-04	2017-01-27	Lupin Ltd	Quinolizinone derivatives as pi3k inhibitors
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX2017008076A (es)	2014-12-19	2018-01-09	Janssen Pharmaceutica Nv	DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
HUE045220T2 (hu)	2014-12-19	2019-12-30	Janssen Pharmaceutica Nv	Imidazopiridazin-származékok mint PI3Kbéta inhibitorok
US9637488B2 (en)	2015-01-29	2017-05-02	Fuqiang Ruan	Heterocyclic compounds as inhibitors of class I PI3KS
UA122332C2 (uk)	2015-02-27	2020-10-26	Інсайт Корпорейшн	Солі інгібітора pi3k і способи їх отримання
WO2016134668A1 (fr) *	2015-02-28	2016-09-01	Sunshine Lake Pharma Co., Ltd.	Composés d'aminopyrimidine substituée et procédés d'utilisation
WO2016183060A1 (fr)	2015-05-11	2016-11-17	Incyte Corporation	Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2016183063A1 (fr)	2015-05-11	2016-11-17	Incyte Corporation	Formes cristallines d'un inhibiteur de pi3k
JP6912460B2 (ja)	2015-10-09	2021-08-04	ヤンセンファーマシューティカエヌ．ベー．	ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体
EP3404021A4 (fr)	2016-01-12	2019-09-11	Nippon Chemiphar Co., Ltd.	Inhibiteur du canal calcique de type t tension-dépendant
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US20190263804A1 (en)	2016-06-16	2019-08-29	Janssen Pharmaceutica Nv	Azabenzimidazole derivatives as pi3k beta inhibitors
KR102472453B1 (ko)	2016-06-16	2022-11-29	얀센 파마슈티카 엔.브이.	Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체
MX2019000512A (es)	2016-07-12	2019-05-02	Bayer Cropscience Ag	Compuestos biciclicos como plaguicidas.
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
EP3601254B1 (fr)	2017-03-29	2022-05-25	Janssen Pharmaceutica NV	Dérivés de pyridopyrazine et de quinoxaline en tant qu'inhibiteurs de pi3k-beta
US20230190717A1 (en) *	2017-04-10	2023-06-22	City Of Hope	P38 gamma inhibitors and method of use thereof
SG11202002032SA (en)	2017-09-22	2020-04-29	Jubilant Epipad LLC	Heterocyclic compounds as pad inhibitors
CA3076476A1 (fr)	2017-10-18	2019-04-25	Jubilant Epipad LLC	Composes imidazo-pyridine a utiliser en tant qu'inhibiteurs de pad
BR112020008851A2 (pt)	2017-11-06	2020-10-20	Jubilant Prodel LLC	composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
PL3704120T3 (pl)	2017-11-24	2024-09-16	Jubilant Episcribe Llc	Związki heterocykliczne jako inhibitory prmt5
BR122023024273A2 (pt)	2018-02-27	2024-02-20	Incyte Corporation	Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
SG11202008950PA (en)	2018-03-13	2020-10-29	Jubilant Prodel LLC	Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3810610A1 (fr)	2018-05-18	2021-04-28	Incyte Corporation	Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MX2020012826A (es)	2018-06-01	2021-03-09	Incyte Corp	Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
AU2019297361B2 (en)	2018-07-05	2024-06-27	Incyte Corporation	Fused pyrazine derivatives as A2A / A2B inhibitors
PY1960131A (es)	2018-08-07	2020-11-20	Syngenta Crop Protection Ag	Compuestos heteroatomáticos bicíclicos activos como pesticidas
ES2974634T3 (es)	2018-12-21	2024-06-28	Celgene Corp	Inhibidores de tienopiridinas de RIPK2
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
ES2995214T3 (en)	2019-03-06	2025-02-07	C4 Therapeutics Inc	Heterocyclic compounds for medical treatment
GB201909190D0 (en) *	2019-06-26	2019-08-07	Ucb Biopharma Sprl	Therapeutic agents
GB201909191D0 (en) *	2019-06-26	2019-08-07	Ucb Biopharma Sprl	Therapeutic agents
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CA3201690A1 (fr)	2020-12-15	2022-06-23	Children's Hospital Medical Center	Composes multi-cycliques inhibiteurs d'irak et de flt3 et leurs utilisations
US11319319B1 (en)	2021-04-07	2022-05-03	Ventus Therapeutics U.S., Inc.	Compounds for inhibiting NLRP3 and uses thereof
US20240254121A1 (en)	2021-05-06	2024-08-01	Bayer Aktiengesellschaft	Alkylamide substituted, annulated imidazoles and use thereof as insecticides
US12331048B2 (en)	2022-10-31	2025-06-17	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2024264188A1 (en) *	2023-04-28	2025-11-06	Kurome Therapeutics, Inc.	Irak inhibitor free base, salts, and polymorphic forms thereof
CN117466785B (zh) *	2023-11-02	2026-03-03	韶远科技（上海)有限公司	一种2-卤代-4-(甲基磺酰基)-1-硝基苯的制备方法
WO2026021573A1 (fr) *	2024-07-26	2026-01-29	InventisBio Co., Ltd.	Composés, leurs procédés de préparation et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
CA1279648C (fr) *	1986-07-11	1991-01-29	Haruo Kuriyama	Derives 2-(4-pyridylaminomethyl)benzimidazole a activite antivirale
EP0530149A1 (fr) *	1991-08-30	1993-03-03	Ciba-Geigy Ag	Parasiticide
US6043062A (en)	1995-02-17	2000-03-28	The Regents Of The University Of California	Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en)	1996-06-01	1996-08-07	Ludwig Inst Cancer Res	Novel lipid kinase
US5858753A (en)	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
US5822910A (en)	1997-10-02	1998-10-20	Shewmake; I. W.	Fishing line tensioning device
WO2003040141A1 (fr) *	2001-09-28	2003-05-15	Bayer Pharmaceuticals Corporation	Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs
US7109337B2 (en) *	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
AR043692A1 (es) *	2003-02-06	2005-08-10	Novartis Ag	2-cianopirrolopirimidinas y sus usos farmaceuticos
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
JP5291616B2 (ja) *	2006-04-26	2013-09-18	ジェネンテック，インコーポレイテッド	ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
WO2008039882A1 (fr) *	2006-09-30	2008-04-03	Sanofi-Aventis U.S. Llc	Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
MX2010003449A (es)	2007-09-26	2010-04-27	Astellas Pharma Inc	Derivado de quinolona.
EP2277881A4 (fr) *	2008-04-18	2011-09-07	Shionogi & Co	Composé hétérocyclique présentant une activité inhibitrice sur p13k
GB0821693D0 (en)	2008-11-27	2008-12-31	Ucb Pharma Sa	Therapeutic agents
EP2396315B1 (fr)	2009-02-13	2016-08-31	UCB Biopharma SPRL	Dérivés de quinoline en tant qu'inhibiteurs de kinases pi3k
EA201270013A1 (ru)	2009-06-25	2012-06-29	Амген Инк.	Гетероциклические соединения и их применение
MX2012006953A (es)	2009-12-18	2012-10-09	Amgen Inc	Compuestos heterociclicos y sus usos.
US8759359B2 (en) *	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors

2011
- 2011-03-30 UY UY0001033304A patent/UY33304A/es not_active Application Discontinuation
- 2011-04-01 JP JP2013502882A patent/JP2013540099A/ja not_active Withdrawn
- 2011-04-01 US US13/078,192 patent/US8575183B2/en active Active
- 2011-04-01 MY MYPI2012004234A patent/MY184620A/en unknown
- 2011-04-01 MA MA35338A patent/MA34212B1/fr unknown
- 2011-04-01 EA EA201291005A patent/EA201291005A1/ru unknown
- 2011-04-01 CN CN2011800269826A patent/CN103221403A/zh active Pending
- 2011-04-01 EP EP11713167A patent/EP2552908A2/fr not_active Withdrawn
- 2011-04-01 KR KR1020127028710A patent/KR20130103309A/ko not_active Withdrawn
- 2011-04-01 MX MX2012011387A patent/MX2012011387A/es not_active Application Discontinuation
- 2011-04-01 TW TW100111649A patent/TW201202219A/zh unknown
- 2011-04-01 CA CA2793897A patent/CA2793897A1/fr not_active Abandoned
- 2011-04-01 BR BR112012025164A patent/BR112012025164A2/pt not_active IP Right Cessation
- 2011-04-01 PE PE2012001829A patent/PE20130339A1/es not_active Application Discontinuation
- 2011-04-01 SG SG2012072526A patent/SG184354A1/en unknown
- 2011-04-01 AR ARP110101102A patent/AR081448A1/es not_active Application Discontinuation
- 2011-04-01 PH PH1/2012/501922A patent/PH12012501922A1/en unknown
- 2011-04-01 WO PCT/US2011/030888 patent/WO2011123751A2/fr not_active Ceased
- 2011-04-01 AU AU2011235031A patent/AU2011235031B2/en not_active Expired - Fee Related
2012
- 2012-09-18 TN TNP2012000449A patent/TN2012000449A1/en unknown
- 2012-10-01 ZA ZA2012/07341A patent/ZA201207341B/en unknown
- 2012-10-02 CL CL2012002769A patent/CL2012002769A1/es unknown
- 2012-10-09 IL IL222288A patent/IL222288A0/en unknown
- 2012-10-30 CO CO12195413A patent/CO6630161A2/es active IP Right Grant
- 2012-11-02 CR CR20120562A patent/CR20120562A/es unknown

Also Published As

Publication number	Publication date
MY184620A (en)	2021-04-09
MX2012011387A (es)	2013-02-26
TW201202219A (en)	2012-01-16
BR112012025164A2 (pt)	2016-06-21
US8575183B2 (en)	2013-11-05
SG184354A1 (en)	2012-11-29
JP2013540099A (ja)	2013-10-31
ZA201207341B (en)	2014-06-25
WO2011123751A3 (fr)	2014-08-07
MA34212B1 (fr)	2013-05-02
CA2793897A1 (fr)	2011-10-06
TN2012000449A1 (en)	2014-01-30
IL222288A0 (en)	2012-12-31
EA201291005A1 (ru)	2013-09-30
AR081448A1 (es)	2012-09-05
US20110245257A1 (en)	2011-10-06
AU2011235031A1 (en)	2012-10-25
PH12012501922A1 (en)	2013-02-04
PE20130339A1 (es)	2013-04-13
CL2012002769A1 (es)	2013-07-05
CN103221403A (zh)	2013-07-24
EP2552908A2 (fr)	2013-02-06
AU2011235031B2 (en)	2014-10-23
WO2011123751A2 (fr)	2011-10-06
KR20130103309A (ko)	2013-09-23
CO6630161A2 (es)	2013-03-01
CR20120562A (es)	2013-03-01

Legal Events

Date	Code	Title	Description
2019-12-18	109	Application deemed to be withdrawn	Effective date: 20191218

Publication	Publication Date	Title
CO6630161A2 (es)	2013-03-01	Compuestos heterocíclicos y sus usos
CO2020010956A2 (es)	2020-10-30	Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CU20200067A7 (es)	2021-04-07	Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5
ECSP19070336A (es)	2019-10-31	Arn terapéutico
PH12015502114A1 (en)	2016-01-25	2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
CL2019003439A1 (es)	2020-03-20	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación.
MX2016011038A (es)	2017-05-12	Compuestos para el tratamiento de trastornos mediados por complemento.
CO2018006475A2 (es)	2018-07-10	Compuestos que inhiben eif4a y métodos relacionados a los mismos
PH12020550201A1 (en)	2024-01-15	N-acyl-n-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
MX2013001970A (es)	2013-08-09	Compuestos de pirrolopirimidina y usos de los mismos.
EA201270013A1 (ru)	2012-06-29	Гетероциклические соединения и их применение
ECSP11010932A (es)	2011-04-29	Compuestos de azaindazol como antagonistas del receptor de ccr1
EA201270051A1 (ru)	2012-05-30	Гетероциклические соединения и их применения
MX385332B (es)	2025-03-18	Moduladores de ror-gamma.
CO6781507A2 (es)	2013-10-31	Novedosos derivados heterociclicos
CU20140048A7 (es)	2014-12-26	Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CR11053A (es)	2009-10-23	Compuestos heterociclicos y sus usos
MX372754B (es)	2020-06-29	Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
EA201491823A1 (ru)	2015-01-30	Гетероциклические соединения и их использование
EP4275746A3 (fr)	2024-01-10	Vésicules extracellulaires issues de cellules de lignée ostéoblastique, à usage thérapeutique et diagnostique
MX2012014983A (es)	2013-04-24	Quinolinas como inhibidores pi3k.
MX389506B (es)	2025-03-20	Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
MX375545B (es)	2025-03-06	Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
AR090705A1 (es)	2014-12-03	Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
DOP2019000220A (es)	2019-11-15	Arn terapeutico